In recent years, numerous studies have revealed that abnormal expression of core effectors—such as YAP/TAZ and MOB1—as well as upstream regulators (e.g., MST1/2, RASSF1A, NF2) is closely associated with patient prognosis, tumor invasiveness, and therapeutic response. This evidence concerns the gene RASSF1 and neoplasm.